Tierney M C, Fisher R H, Lewis A J, Zorzitto M L, Snow W G, Reid D W, Nieuwstraten P
Geriatric Research Programme, Sunnybrook Medical Centre, University of Toronto, Ontario, Canada.
Neurology. 1988 Mar;38(3):359-64. doi: 10.1212/wnl.38.3.359.
Neuropathologic confirmation is required to validate the NINCDS-ADRDA Work Group criteria for the clinical diagnosis of Alzheimer's disease (AD). Neuropathologic inclusion and exclusion criteria for AD, however, are not uniform. The purpose of this investigation was to examine the confirmation rate for the Work Group criteria against differing neuropathologic criteria for AD. The sample consisted of 57 cases, 22 of which had received a clinical diagnosis of AD. Nine neuropathologic criteria for AD were applied in a blind fashion to each of the 57 cases. Our results indicated that, depending on the neuropathologic criteria applied, the clinicopathologic agreement ranged from 64% to 86%. These findings demonstrate the need for universally accepted neuropathologic and clinical criteria for AD.
需要神经病理学确认来验证美国国立神经疾病与中风研究所 - 阿尔茨海默病及相关疾病协会(NINCDS - ADRDA)工作组关于阿尔茨海默病(AD)临床诊断的标准。然而,AD的神经病理学纳入和排除标准并不统一。本研究的目的是根据不同的AD神经病理学标准,检验工作组标准的确诊率。样本包括57例病例,其中22例临床诊断为AD。对这57例病例中的每一例均以盲法应用9种AD神经病理学标准。我们的结果表明,根据所应用的神经病理学标准,临床病理一致性在64%至86%之间。这些发现表明需要有普遍接受的AD神经病理学和临床标准。